PROGNOSTIC FACTOR ANALYSIS OF THE SURVIVAL OF ELDERLY PATIENTS WITH AML IN THE MRC AML11 AND LRF AML14 TRIALS

摘要: This analysis, of 2483 patients with acute myeloid leukaemia (AML) aged 60+ years entered into two UK trials, was performed to determine the baseline parameters related survival and develop a risk index. The Medical Research Council (MRC) AML11 trial (n = 1071) used to develop the index; this validated using data from Leukaemia Research fund (LRF) AML14 on 1137 intensively (AML14I) 275 nonintensively (AML14NI) treated patients. In AML11, cytogenetic group, age, white blood count, performance status type AML (de novo, secondary) were all highly significantly prognosis in multivariate analysis. The regression coefficients were define good, standard poor risk groups, 1-year 53%, 43% 16% respectively (P < 0AE0001). The index showed very good discrimination both AML14I and AML14NI (both P 0AE0001), thereby providing validation, although survival in groups AML14NI. The factors for older AML similar those younger ones of patient relatively possible. These apply non-intensively treated patients. Randomized trials intensive versus non-intensive therapy are needed which types patient should be given of treatment.